Title : A phase I/II study of the Janus kinase (JAK)1 and 2 inhibitor ruxolitinib in patients with relapsed or refractory acute myeloid leukemia.

Pub. Date : 2015 Mar

PMID : 25441108






2 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 One patient with multiple relapses after 7 lines of therapy had a CRp at a ruxolitinib dose of 200 mg b.i.d. ruxolitinib C-reactive protein Homo sapiens
2 CONCLUSION: In this cohort of heavily pretreated patients with relapsed or refractory acute leukemias, ruxolitinib was overall reasonably well tolerated, with 1 patient achieving CRp. ruxolitinib C-reactive protein Homo sapiens